by quantitative real-time polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA). Macrophage polarization and its mechanism were evaluated by flow cytometry and western blot. Additionally, toll-like receptor 4 (TLR4) small interfering RNA and mitogen-activated protein kinase (MAPK) inhibitors were used to further confirm the molecular mechanism of curcumin on macrophage polarization.
RESULTS
The content of cholesterol in subcutaneous adipose tissue in control group, model group, Niacin treatment group was (3.13 AE 0.19), (20.81 AE 1.97) and (4.00 AE 0.81) mg/g, respectively. Compared with model group, Niacin treatment could increase the expression of LXRa, ABCA1 and ABCG1 mRNA 144%, 47.3% and 73.8%, respectively. And furthermore, it could also downregulate the level of serum total triglyceride, total cholesterol and LDL cholesterol, upregulate the level of serum HDL cholesterol, apoA-I. Pearson correlation analysis showed that there was a positive relation between the content of cholesterol in arterial wall and the ratio of intima/media thickness (r¼0.58, P<0.05). In addition to those above, Niacin treatment could thin the intima thickness, decrease the ratio of intima/media thickness and downregulate the subendothelium lipid-accumulation, especially cholesterol -accumulation.
CONCLUSIONS Niacin treatment may promote the reverse cholesterol transport of peri-adipose tissue, bring the changes of serum lipid profile, and furthermore influence the sub-endothelium lipid-accumulation, especially cholesterol -accumulation, and subsequently reverse the aortic atherosclerosis.
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Renalase Protects the Cardiomyocytes of Sprague-Dawley Rats Against Ischemia and Reperfusion Injury by Reducing Myocardial Cell Necrosis and Apoptosis Xiaogang LI, Weihong Jiang The Third Xiangya Hospital of Central South University OBJECTIVES Renalase, a novel flavoprotein expressed in the kidney and heart, reduces renal tubular necrosis and apoptosis, which suggests that it might protect against myocardial ischemia reperfusion injury (MIRI) in the same manner. This experiment sought to explore the effects of renalase on Sprague-Dawley (SD) rats subjected to MIRI.
METHODS
We used Lentivirus-mediated RNA interference (RNAi) to inhibit the renalase gene expression in the heart tissue via pericardial cavity injection. The MIRI animal modal was established by blocking the left anterior descending artery for 45mins followed by 4h of reperfusion. Real-time PCR and western blotting were used to detect renalase expression in the heart tissue. Double staining and TUNEL were used to detect the necrosis and apoptosis in the myocardial cells, respectively.
RESULTS All rats subjected to MIRI exhibited lower levels of renalase in the heart tissue than did the sham-operated group (P<0.05, n¼6). The (RNAi) group rats exhibited lower renalase levels than did the controls and also exhibited more serious necrosis (7.12AE0.56% vs. 3.32AE0.93%, P<0.05, n¼6) and apoptosis (151.8AE8.2 vs. 66.8AE6.5, P<0.05, n¼6); however, pretreatment with the recombinant renalase significantly reduced myocardial cell necrosis (1.51AE0.12% vs. 4.13AE0.02%, P<0.05, n¼6) and apoptosis (21.3AE5.0 vs. 52.6AE10.4, P<0.05, n¼6) relative to the control rats.
CONCLUSIONS Exogenous recombinant renalase protein reduced myocardial cell necrosis and apoptosis. Recombinant renalase protein might be a new cardiovascular drug for ischemia/IR injury.
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Roles of (p)rr Gene Activation in the Heart in Hypertensive Rats Yanling Zhang, Lulu Ma, Junyan Wu Institute of Neurobiology, Taishan Medical University, Taian, China OBJECTIVES Discovery of (pro)renin receptor (P)RR uncovered a novel function of (pro)renin as receptor ligand in addition to enzyme and its precursor, but the roles and mechanisms of (P)RR on the endorgan damage remains unclear so far. Recently, some findings support the (pro)renin-(P)RR interaction at exceptionally high (pro)renin levels in vitro. However, the conflicting results obtained with handle region peptide (HRP) in vivo and in vitro argue against the idea that this drug truly blocks the (pro)renin-(P)RR interaction in the intact animals. In this study, we investigated the roles of cardiac (P)RR and its downward signals on cardiac hypertrophy in hypertensive rats with abdominal aortic constriction, following treatment of HRP and PLC-b3 inhibitor, U73122.
METHODS Seventy-five SD rats were divided into 5 groups (n¼15 each group) as following: sham operated (SO), rats with the aortic ligation (AL), AL rats were given HRP (4mg kg -1 d -1 , SC), AL rats given U73122 (40mg kg -1 d -1 , SC) and AL rats given HRPþU73122. MAP was recorded using a tail-cuff method. After 4 weeks of treatment, levels of (P)RR, PLC-b3, PKC-a and ERK1/2 in the heart were examined by RT-PCR and western blot. The surface area of cardiomyocytes was measured.
RESULTS The levels of (P)RR and PLC-b3 significantly increased in the left ventricle in hypertensive rats (P<0.01, respectively). The surface area of cardiomyocytes and MAP rose markedly (P<0.01). HRP significantly decreased the level of (P)RR and U73122 suppressed PLCb3 expression. Treatment of both HRP and U73122 significantly decreased levels of PKC-a, ERK1/2 and Raf-1 in the heart (P<0.001). Meanwhile, the surface area of cardiomyocytes and MAP were decreased after treatment (P<0.01).
CONCLUSIONS This study demonstrates that (P)RR inhibitor, HRP and PLC-b3 inhibitor, U73122 decreased levels of (P)RR, PLC-b3, PKCa, ERK1/2 and Raf-1 in the heart, respectively. Meanwhile, administration of both reagents lowered the surface area of cardiomyocytes and MAP. These findings indicate that cardiac (P)RR may activate PLC-b3, PKC, ERK1/2 and Raf-1 signals and lead to hypertension and cardiac hypertrophy.
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GW26-e1007 Protective Effects and Mechanism of Penehyclidine Hydrochloride on Myocardial Ischemia Reperfusion Injury in rats
Duomao Lin, Yanyan Xue, Zhaoqi Wang, Jun Ma Beijing Anzhen Hospital, Capital Medical University OBJECTIVES To investigate the effects and mechanisms of penehyclidine hydrochloride (PHC) on myocardial ischemia reperfusion injury(IRI).
METHODS A rat model of myocardial IRI was established by the ligation of left anterior descending coronary artery for 30 min followed by 3 h perfusion. The rats were randomly divided into 6 groups (n¼18 in each group): a). Sham group: The rats underwent sham surgery without LAD ligation; b). ShamþH-PHC group: The rats were administrated with high dose of penehyclidine hydrochloride (H-PHC; 1 mg/kg bodyweight)by i.v. 30min before sham surgery; c). Ischemia reperfusion (I/R) group: The rats were subjected to a 30min LAD coronary artery ligation followed by 3h reperfusion; d). I/RþL-PHC group: The rats were administrated with low dose of PHC (L-PHC; 0.1 mg/kg bodyweight) 30min before I/R; e). I/RþM-PHC group: The rats were administrated with moderate dose of PHC (M-PHC; 0.3 mg/kg bodyweight) 30min before I/R; f). I/RþH-PHC group: The rats were injected with H-PHC (1 mg/kg bodyweight) 30min before I/R. Cardiac function was measured by echocardiography after 3h reperfusion. Blood samples were collected. Then, the activities and levels of myocardial enzymes and antioxidant enzymes in serum were detected. Evans blue/TTC double staining was performed to assess infarct size. Cardiomyocyte apoptosis was evaluated by TUNEL assay. The release of inflammatory cytokines and inflammatory mediators was detected by ELISA. Western blot was performed to analyze the expression of COX-2, p-IkB, IkB and NF-kB.
RESULTS
We found that PHC improved cardiac function by elevating ejection fraction (EF), fractional shortening (FS) and left ventricular end systolic pressure (LVESP), and downregulating left ventricular end-diastolic pressure (LVEDP). PHC treatment remarkably decreased the activities of creatine kinase (CK), aspartate aminotransferase (AST), lactate dehydrogenase (LDH) and malondialdehyde (MDA) content, and increased superoxide dismutase (SOD) activity. Additionally, PHC reduced the infarct size and the apoptotic rate of cardiomyocytes in a dose dependent manner. Administration of PHC significantly decreased serum IL-1b, TNF-a, PEG-2 and IL-6 levels and myocardium COX-2 level. Meanwhile, the expression levels of p-IkB and NF-kB were downregulated, while IkB expression was upregulated. These results suggest that PHC exert dose-dependent effects on I/R-induced myocardial injury by inhibiting oxidative stress, apoptosis and inflammation, and reduce the levels of nuclear NF-kB and p-IkB.
CONCLUSIONS PHC presented significantly dose dependent effects on myocardial IRI by inhibiting inflammation, oxidative stress and apoptosis, and reducing the level of nuclear NF-kB and p-IkB. OBJECTIVES Antiplatelet treatment has been proved to be an effective strategy for the prevention of cardiovascular disease (CVD). However, a major disadvantage of this strategy is the increasing risk of hemorrhages. Developing new platelet inhibitors with minimal adverse effects is important for clinical treatment of CVD. AtractylenolideII(ATII) and III(ATIII) are the major active components in Atracylodes macrocephala. The effects of the components including anti-inflammatory and anti-cancer have been demonstrated. However, their effects on platelet activation are unknown. Therefore, We explored the effects of ATII and ATIII on platelet activities such as platelet aggregation, platelet spreading, thrombus formation and so on. We also investigated the effects of ATII and ATIII on essential signaling mediator in platelet activation.
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METHODS Human platelets were adjusted to 3Â10⁸platelets/ml for platelet aggregation. ATII, ATIII and Acetylsalicylic acid were incubated with the platelets for 3 min prior to stimulation, respectively. When the platelet aggregation was terminated, the target proteins were detected to detect the phosphorylation levels of signaling molecules by Western blotting. For platelet spreading on immobilized fibrinogen, platelets were incubated with ATII and ATIII respectively for 3min and allowed to spread on immobilized fibrinogen. The colt reaction was done as following, human platelet-depleted plasma was mixed with washed human platelets to a concentration of 4Â10 8 /ml and was incubated with ATIIand AT III for 3min respectively. Plasma was induced to coagulate with 0.4U/ml thrombin. We examined thrombosis formation by FeCl 3 -induced carotid artery injury murine thrombosis model. After mice were treatment with ATII(ATIII) at 60mg/kg dose by oral administration, carotid artery blood flow was monitored.
RESULTS Compared to Acetylsalicylic acid, ATII(ATIII) inhibited platelet aggregation with lower concentration(10mM) in response to athrombin and collagen. Akt and other signaling molecules such as p-38, Erk have been proved to play critical roles in platelet activation. Akt Ser473phosphorylation levels were significantly diminished for ATII(ATIII) treatment in response toathrombin, but no changes were found in the phosphorylation levels of p-38 and Erk. The average size of the platelets that spread on Fg were 1900.4AE1059.86 pixels for ATII10mM,2185AE1687.07 pixels for ATIII10mM versus 9508.76AE2107.95 pixels for the platelets in the presence of DMSO. In the FeCl 3 -induced carotid artery thrombosis model, the average time to first occlusion was 12.19 min for the ATII,and 9.67 min for ATIII mice, in contrast to 6.76min in control mice. The average ratio of clot retraction of ATII with platelets was 0.1659AE0.0115, ATII with platelets was 0.2892AE0.0118 versus DMSO with platelets 0.7183AE0.0359.
CONCLUSIONS The work demonstrates that ATII and AT III inhibit platelets aggregation, spreading, clot retraction and arterial thrombosis formation in vivo. The results suggest that ATII& III have the potential to be an efficient platelet inhibitors. OBJECTIVES Our previous studies found that cardiac stem cells (CSCs) transplantation improved the ventricular fibrillation threshold (VFT) in myocardial infarction (MI) rats. However, the mechanisms remain unclear. Therefore, we sought to explore the mechanisms.
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METHODS MI was induced in 30 male Sprague-Dawley rats. 2 weeks later, animals were randomized to receive 5Â10 6 CSCs labeled with PKH26 in phosphate buffer solution(PBS)(20 rats) or PBS (10 rats) alone injection into the infarcted anterior ventricular free wall. After that, 10 rats with CSCs transplantation received PHA665752 (Hepatocyte Growth Factor/c-Met Inhibitor, 15mg/kg) in PBS and DMSO (PHA665752 group), 10 rats with CSCs transplantation received PBS and DMSO (CSC group) and 10 rats with PBS injection received PBS and DMSO (PBS group) via tail vein injection every day for 2 weeks. Then the VFTs were measured. Labeled CSCs were observed in 5mm cryostat sections from each heart to detect the myocardial fibrosis. Masson detection showed that the myocardial fibrosis in PHA665752 group was obviously more severity than that in CSCs group. CONCLUSIONS PHA665752, hepatocyte growth factor/c-Met inhibitor, reduces the VFT and enhances the myocardial fibrosis in MI rats treated with CSCs transplantation, which indicates that CSCs paracrining hepatocyte growth factor ameliorate myocardial fibrosis leading to VFT improvement.
RESULTS
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Changes of Small-conductance calcium-activated K(þ) channels 3 (SK3) in Patients with Persistent Atrial Fibrillation OBJECTIVES We had reported that the current density of apaminsensitive SK channels was significantly increased in AF group with persistent atrial fibrillation than SR group. The purpose of this study was to investigate whether the current density increase of SK channels in patients with persistent atrial fibrillation was because of its differential expression between the sinus rhythm (SR) and persistent atrial fibrillation patients and whether SK3 channel is involved in electrical remodeling of human persistent atrial fibrillation.
METHODS
The right atrial appendage myocytes were obtained from 16 sinus rhythm (SR) and 14 persistent atrial fibrillation patients 
